£4.8m contracts awarded

Abingdon Health PLC

30 March 2026

 

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

£4.8m contracts awarded for development of multiplex lateral flow systems

York, U.K. 30 March 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that it has been awarded a series of significant contracts with a USA-based customer to develop, and scale up to manufacture several multiplex quantitative lateral flow assay systems measuring multiple biomarkers simultaneously in human samples. The contracts include full programme management, the management of regulatory processes, and analytical and clinical performance services.

The contracts have a total value of approximately £4.8 million based on the agreed scope of work and will be delivered over a circa 27-month period commencing immediately. These contracts will be executed via a series of work packages based on agreed milestones, with potential further scope beyond that period including appointment as legal manufacturer. The contracts represent an important validation of Abingdon Health's full programme management CDMO service which offers development from feasibility and initial regulatory pathway provision through to product manufacture and multi-territory regulatory approvals.

The programmes of work will leverage the Group's established and growing capabilities in lateral flow test development and manufacture in its York, UK and Madison, Wisconsin, USA facilities. In addition, the programmes will utilise its regulatory services companies, CS Lifesciences and IVDeology, as well as analytical and clinical performance evaluation services provided by Abingdon Analytical at its Doncaster, UK facilities. It underscores Abingdon Health's position as a leading provider of integrated CDMO/CRO services for rapid diagnostic tests and med-tech.

Dr Chris Hand, Executive Chairman, commented: "We are delighted to announce these significant contract awards. Our multi-disciplinary teams of highly skilled in-house experts in the fields of immunodiagnostics, lateral flow development and manufacture, regulatory approvals, performance evaluation, and programme management continue to resonate with our customers. These contract wins reinforce our position as the 'go-to' experts for the provision of end-to-end lateral flow test development and programme management: in this case for complex multiplex quantitative test devices."

LEI - 213800XFI4WV3FBILO20

Enquiries:

Abingdon Health plc	www.abingdonhealth.com/investors/
Chris Hand, Executive Chairman		Via Walbrook PR
Tom Hayes, CFO
Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)		Tel: [phone]
Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance) Nigel Birks (Life Science Specialist Sales)
Walbrook PR (Media & Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.  

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.  The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities.

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

 

END